|
[1]
|
World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCoV). [2021-1-25].https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCoV) |
|
[2]
|
GHS Index-Global Health Security Index: Building Collective Action and Accountability. Nuclear Threat Initiative and Johns Hopkins Bloomberg School of Public Health, 2019. https://www.ghsindex.org/. [2021-1-25].https://www.ghsindex.org/ |
|
[3]
|
Center for Systems Science and Engineering, Johns Hopkins University. COVID-19 dashboard. https://coronavirus.jhu.edu/map.html. [2021-1-25].https://coronavirus.jhu.edu/map.html |
|
[4]
|
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020;395(10225):689 − 97. http://dx.doi.org/10.1016/S0140-6736(20)30260-9CrossRef
|
|
[5]
|
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. https://covid19.who.int/. [2021-1-25].https://covid19.who.int/ |
|
[6]
|
Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet 2020;395(10233):1382 − 93. http://dx.doi.org/10.1016/S0140-6736(20)30746-7CrossRef
|
|
[7]
|
World Health Organization. WHO coronavirus disease (COVID-19) dashboard: situation by country, territory & area. https://covid19.who.int/table. [2021-1-25].https://covid19.who.int/table |
|
[8]
|
Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020;368(6493):860 − 8. http://dx.doi.org/10.1126/science.abb5793CrossRef
|
|
[9]
|
Chinese Center for Disease Control and Prevention. COVID-19 vaccine Q&A. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_12208/202101/t20210107_223665.html. [2021-1-25]. (In Chinese). http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_12208/202101/t20210107_223665.html |
|
[10]
|
Peiris M, Leung GM. What can we expect from first-generation COVID-19 vaccines? Lancet 2020;396(10261):1467 − 9. http://dx.doi.org/10.1016/S0140-6736(20)31976-0CrossRef
|
|
[11]
|
Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun 2021;12(1):29. http://dx.doi.org/10.1038/s41467-020-20226-9CrossRef
|
|
[12]
|
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020;370(6521):1227 − 30. http://dx.doi.org/10.1126/science.abd7728CrossRef
|
|
[13]
|
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020;5(12):1598 − 607. http://dx.doi.org/10.1038/s41564-020-00813-8CrossRef
|
|
[14]
|
Buss LF, Prete CA Jr, Abrahim CMM, Mendrone A Jr, Salomon T, de Almeida-Neto C, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 2021;371(6526):288 − 92. http://dx.doi.org/10.1126/science.abe9728CrossRef
|
|
[15]
|
Naveca F, Da Costa C, Nascimento V, Souza V, Corado A, Nascimento F, et al. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil. https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596. [2021-1-25].https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596 |
|
[16]
|
Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Lambson BE, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv 2021. http://dx.doi.org/10.1101/2021.01.18.427166.http://dx.doi.org/10.1101/2021.01.18.427166 |
|
[17]
|
National Academies of Sciences, Engineering, and Medicine. Framework for equitable allocation of COVID-19 vaccine. Washington, DC: The National Academies Press. 2021. http://dx.doi.org/10.17226/25917.http://dx.doi.org/10.17226/25917 |
|
[18]
|
Herzog LM, Norheim OF, Emanuel EJ, McCoy MS. Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. BMJ 2021;372:m4853. http://dx.doi.org/10.1136/bmj.m4853CrossRef
|